AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data
Article Title: AbbVie’s Rinvoq is Approved in Giant Cell Arteritis; Relmada Shares Bladder Cancer Data Publication Date: April 29, 2025 Yesterday, US regulatory agency FDA approved AbbVie’s JAK inhibitor blockbuster Rinvoq to treat adults with giant cell arteritis. Rinvoq’s expansion…